Results 181 to 190 of about 1,333,101 (244)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

Central European Journal of Immunology
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou   +9 more
doaj   +1 more source

Synergistic exacerbation of oral mucositis caused by IL-23 deficiency and oral <i>Candida albicans</i> exposure. [PDF]

mBio
Dillon JT, Hickey MT, Saul-McBeth J, Glanz T, Daboul Y, Byreddy YR, Hohl R, Kratch JM, Thakker JA, Gaffen SL, Gibbs J, Conti HR.   +11 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany. [PDF]

J Clin Med
Farrag K, Grimm L, Dahmer I, Stratmann K, Dienethal A, Sprinzl K, Lande R, Zeuzem S, Blumenstein I, Kubesch A.   +9 more
europepmc   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis). [PDF]

Dermatol Ther (Heidelb)
Trovato E, Cartocci A, Gaiani F, Messina F, Mastorino L, Macagno N, Carugno A, Campoli M, Fargnoli MC, Lora V, Rossi A, Gioacchini H, Potestio L, D'Agostino GM, Maurelli M, Girolomoni G, Romanelli M, Dini V, Loconsole F, Satolli F, Pagnanelli G, Lasagni C, Michelerio A, Dragotto M, Malagoli P, Zerbinati N, Orsini D, Campanati A, Megna M, Bianchelli T, Italian Landscape Group, Costanzo A, Ribero S, Narcisi A.   +33 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs. [PDF]

J Exp Clin Cancer Res
Talarico G, Lecchi M, Zanichelli A, Portararo P, Botti L, Cappelletti V, Costanza M, Piva A, Pratesi P, Bertolini F, Di Nicola M, Tripodo C, Cancila V, Pupa SM, Colombo MP, Chiodoni C, Verderio P, Sangaletti S.   +17 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source